-
Start Preamble
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 15, 2002, Ansys Technologies, Inc., 25200 Commercentre Drive, Lake Forest, California 92630, made application by renewal to the Drug Enforcement Administration (DEA) for registration as Start Printed Page 45764a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Phencyclidine (7471) II 1-Piperidinocyclohexane-carbonitrile (8603) II Benzoylecgonine (9180) II The firm plans to manufacture the listed controlled substances to produce standards and controls for in-vitro diagnostic drug testing systems.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 9, 2002.
Start SignatureDated: June 18, 2002.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 02-17206 Filed 7-9-02; 8:45 am]
BILLING CODE 4410-09-M
Document Information
- Published:
- 07/10/2002
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 02-17206
- Pages:
- 45763-45764 (2 pages)
- PDF File:
- 02-17206.pdf